会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • PROCESS FOR MAKING ANTIMICROBIAL QUINOLONYL LACTAMS
    • 制备抗微生物喹诺酮类药物的方法
    • WO1993007154A1
    • 1993-04-15
    • PCT/US1992008246
    • 1992-09-28
    • PROCTER & GAMBLE PHARMACEUTICALS, INC.
    • PROCTER & GAMBLE PHARMACEUTICALS, INC.WHITE, Ronald, EugeneDEMUTH, Thomas, Prosser, Jr.
    • C07D499/88
    • C07D505/00C07D477/02C07D499/88Y02P20/55
    • The present invention provides methods of making compounds of the structure [Q - L ] - L - [L - B], wherein Q is a quinolone moiety; B is a beta-lactam moiety; L, L , and L together comprise a carbamate-containing linking moiety, comprising the steps of: 1) reacting a lactam compound of the formula B-L -H with phosgene to form an intermediate compound of the formula B-L -C(=O)-Cl, where L is oxygen; and 2) coupling said intermediate compound with a quinolone compound of the formula Q-l -R , wherein L is nitrogen; R is hydrogen, Si(R )3, or Sn(R )3; and R is lower alkyl. Preferably, the process additionally comprises steps prior to the reacting and coupling steps where esters of the lactam and quinolone compounds are made. Also preferably, the coupling step comprises adding a solution containing the quinolone compound to a solution containing the intermediate compound. The process steps are also preferably performed at a temperature of from about -80 DEG C to about 0 DEG C. Preferred antimicrobial compounds made by these processes are those where the beta-lactam moiety is a penem.
    • 本发明提供了制备[Q-L 1] -L- [L 2 -B]结构的化合物的方法,其中Q是喹诺酮部分; B是β-内酰胺部分; L,L 1和L 2一起包含含氨基甲酸酯的连接部分,包括以下步骤:1)将式BL 4 -H的内酰胺化合物与光气反应以形成中间体化合物 式(4)-C(= O)-Cl,其中L 4为氧; 和2)将所述中间体化合物与式Q-l 3-R 44的喹诺酮化合物偶联,其中L 3是氮; R 44是氢,Si(R 45)3或Sn(R 45)3; R 45为低级烷基。 优选地,该方法还包括在制备内酰胺和喹诺酮化合物的酯的反应和偶联步骤之前的步骤。 还优选地,偶联步骤包括将含有喹诺酮化合物的溶液加入到含有中间体化合物的溶液中。 方法步骤还优选在约-80℃至约0℃的温度下进行。通过这些方法制备的优选的抗微生物化合物是其中β-内酰胺部分是青铜的那些。
    • 6. 发明申请
    • PENEM DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    • 派宁衍生物,其制剂和含有它们的药物组合物
    • WO1994006803A1
    • 1994-03-31
    • PCT/EP1993002493
    • 1993-09-15
    • A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE ...ISTITUTO LUSOFARMACO D'ITALIA S.P.A.ALTAMURA, MariaARCAMONE, Federico, MariaPERROTTA, EnzoPESTELLINI, VittorioSBRACI, PieroCASCIO, Giuseppe
    • A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE ...ISTITUTO LUSOFARMACO D'ITALIA S.P.A.
    • C07D499/88
    • C07D499/88
    • Described are penems derivatives of general formula (I) wherein R1 is chosen in the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl, optionally protected C1-C6 hydroxyalkyle; R2 is chosen in the group consisting of carboxyl group free or esterified with a group easily activated "in vivo", carboxylate anion; R3 is chosen in the group consisting of H, C1-C4 alkyl optionally substituted; R4 is chosen in the group consisting of: H, C1-C6 alkyl optionally substituted, C1-C6 hydroxyalkyl optionally substituted, C1-C6 mercaptoalkyl optionally substituted, C1-C6 aminoalkyl optionally substituted, C1-C6 alkyl substituted by a quaternary ammonium group, C1-C6 carboxyalkyl optionally substituted, cycloalkyl, aryl, arylalkyl, heterocyclyl-alkyl optionally substituted, saturated or unsaturated heterocycle wherein the heteroatoms in the heterocyclic ring can be N, O, S, or R3 and R4 linked together form a heterocyclic ring having 3-7 atoms, optionally substituted, saturated or unsaturated which can contain other heteroatoms as O, N, S. R5 and R6 independently from one another are chosen in the group consisting of: H, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 mercaptoalkyl, C1-C6 aminoalkyl, alkenyl, cycloalkyl, aryl, arylalkyl, alkylaryl, heterocyclyl-alkyl, C1-C6 alkyl carboxyamide wherein the alkyl group can be linear or branched (all these groups optionally substituted), or R5 and R6 taken together form an heterocyclic ring having 3-7 atoms optionally substituted, n is chosen in the group consisting of: 1, 2, 3; and their pharmaceutically acceptable salts.
    • 描述的是通式(I)的青蒿衍生物,其中R 1选自H,C 1 -C 6烷基,C 1 -C 6烷氧基,C 3 -C 7环烷基,任选保护的C 1 -C 6羟基烯烃; R2选自无羧基或酯基化,易于活化的“体内”,羧酸根阴离子; R3选自H,任选取代的C 1 -C 4烷基; R4选自:任选取代的H,任选取代的C 1 -C 6烷基,任选取代的C 1 -C 6羟基烷基,任选取代的C 1 -C 6巯基烷基,任选取代的C 1 -C 6氨基烷基,被季铵基团取代的C 1 -C 6烷基, C 1 -C 6羧基烷基任选取代的,环烷基,芳基,芳基烷基,杂环基 - 烷基任选取代的饱和或不饱和杂环,其中杂环中的杂原子可以是N,O,S或R 3和R 4连接在一起形成具有3 -7个原子,任选取代的,饱和或不饱和的,其可以含有其它杂原子作为O,N,S。R5和R6彼此独立地选自:H,C1-C6烷基,C1-C6羟基烷基,C1 -C 6巯基烷基,C 1 -C 6氨基烷基,烯基,环烷基,芳基,芳基烷基,烷基芳基,杂环基 - 烷基,C 1 -C 6烷基羧酰胺,其中烷基可以是直链或支链(所有这些基团任选取代) d R6一起形成任选取代的具有3-7个原子的杂环,n选自:1,2,3; 及其药学上可接受的盐。